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Abstract: Extracellular heat shock proteins (ex-HSPs) have been found in exosomes, oncosomes,
membrane surfaces, as well as free HSP in cancer and various pathological conditions, also known
as alarmins. Such ex-HSPs include HSP90 (α, β, Gp96, Trap1), HSP70, and large and small HSPs.
Production of HSPs is coordinately induced by heat shock factor 1 (HSF1) and hypoxia-inducible
factor 1 (HIF-1), while matrix metalloproteinase 3 (MMP-3) and heterochromatin protein 1 are novel
inducers of HSPs. Oncosomes released by tumor cells are a major aspect of the resistance-associated
secretory phenotype (RASP) by which immune evasion can be established. The concepts of RASP are:
(i) releases of ex-HSP and HSP-rich oncosomes are essential in RASP, by which molecular co-transfer
of HSPs with oncogenic factors to recipient cells can promote cancer progression and resistance
against stresses such as hypoxia, radiation, drugs, and immune systems; (ii) RASP of tumor cells can
eject anticancer drugs, targeted therapeutics, and immune checkpoint inhibitors with oncosomes;
(iii) cytotoxic lipids can be also released from tumor cells as RASP. ex-HSP and membrane-surface
HSP (mHSP) play immunostimulatory roles recognized by CD91+ scavenger receptor expressed
by endothelial cells-1 (SREC-1)+ Toll-like receptors (TLRs)+ antigen-presenting cells, leading to
antigen cross-presentation and T cell cross-priming, as well as by CD94+ natural killer cells, leading
to tumor cytolysis. On the other hand, ex-HSP/CD91 signaling in cancer cells promotes cancer
progression. HSPs in body fluids are potential biomarkers detectable by liquid biopsies in cancers and
tissue-damaged diseases. HSP-based vaccines, inhibitors, and RNAi therapeutics are also reviewed.
Keywords: heat shock protein (HSP); exosome; oncosome; alarmin; immunology; immune evasion;
resistance-associated secretory phenotype (RASP); immune surveillance; hypoxia; biomarker
1. Introduction
Heat shock proteins (HSP) were initially found in cells, although later studies discovered
extracellularly released HSP (ex-HSP), membrane-surface HSP (mHSP), and extracellular vesicles (EVs)
such as HSP-rich oncosomes/exosomes [1] (Figure 1). Tumor cells are often exposed to stresses such
as hypoxic stress, immune response, inflammatory stress, microbial stimuli, and therapeutic stress.
These stresses induce HSPs, molecular chaperones essential for protein folding and balancing between
proteostasis and proteolysis, and play anti-apoptotic roles in cancer [2–5].
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Figure 1. Extracellular, vesicular, and membrane heat shock proteins (HSPs). Extracellular vesicles 
(EVs) are often a heterogeneous mixture of exosomes, ectosomes (also known as microvesicles, MVs), 
oncosomes, large oncosomes, and apoptotic bodies. Exosomes are secreted via membrane fusion of 
multivesicular bodies (MVBs), thereby intraluminal vesicles (ILVs) are exocytosed (top left). HSP90 
was shown to mediate MVB-to-plasma-membrane fusion. Distinctively, the shedding of the plasma 
membrane generates ectosomes (center). Cell-free, vesicle-free HSPs can be released from cells upon 
cell damage and stress (the so-called alarmin or chaperokine). Transmembrane proteins (TMP) such as 
CD91 can keep binding of HSPs on the surface of EVs and cells (blue bars and red balls). Membrane-
surface HSPs (mHSP) are known as tumor antigens (red). Intracellular HSPs can be kept bound to the 
intracellular domains of the TMPs, such as epidermal growth factor receptor (EGFR) family members 
on the cells and EVs. EVs are often taken up by recipient cells in a variety of ways such as endocytosis, 
macropinocytosis, membrane fusion, and phagocytosis (right). 
Meanwhile, ex-HSPs, including mHSP, HSP-rich exosomes, and oncosomes, play key roles in 
intercellular communication in cancer, immunity, and various pathological conditions (Table 1). 
HSPs are released from cells either by passive release, e.g., from damaged, stressed, or dead cells, or 
active release, including secretion of HSP-containing exosomes. Free ex-HSPs have been also called 
alarmin or chaperokine. Exosome HSPs were initially found in B cells, from which Hsp27, Hsc70, 
Hsp70, and Hsp90 are released with exosomes upon heat shock stress [6]. Proteomics revealed that 
oral cancer oncosomes are enriched in HSP90 members, HSP70 members, Hsc70, HSP105, and 
chaperonin [1]. Notably, HSP90α is highly expressed in cancer cells and secreted to extracellular 
space as free HSP90α [5] as well as cargo of oncosome [1]. Additionally, HSP90β, TRAP1, and some 
members of HSP70 are found in oncosomes [1]. However, the mechanism by which HSPs are 
incorporated within the vesicles and their biological significance is still unknown. We here propose 
two models of EV-HSPs: (i) intra-vesicular packaged HSPs and (ii) EV-membrane associated HSPs 
on the outer surface of EVs (Figure 1). 
Ex-HSP, EV-HSP, and mHSP can bind to cell surface receptors (i) stimulating intracellular 
signaling pathways, (ii) taken up by endocytosis, or (iii) molecularly transferred to recipient cells (see 
Section 4). Such recipient cells include various immune cells, cancer cells themselves, as well as 
potential cancer stem cells [CSC, also known as cancer-initiating cells (CIC)], epithelial cells [7], 
cancer-associated fibroblasts (CAFs), mesenchymal stem cells (MSC), tumor endothelial cells (TEC), 
and lymphatic endothelial cells. 
Figure 1. Extracellular, vesicular, and membrane heat shock proteins (HSPs). Extracellular vesicles
(EVs) are often a heterogeneous mixture of exosomes, ectosomes (also known as microvesicles, MVs),
oncosomes, large oncosomes, and apoptotic bodies. Exosomes are secreted via membrane fusion of
multivesicular bodies (MVBs), thereby intraluminal vesicles (ILVs) are exocytosed (top left). HSP90
was shown to mediate MVB-to-plasma-membrane fusion. Distinctively, the shedding of the plasma
membrane generates ectosomes (center). Cell-free, vesicle-free HSPs can be released from cells upon cell
damage and stress (the so-called alarmin or chaperokine). Transmembrane proteins (TMP) such as CD91
can keep binding of s on the surface of EVs and cells (blue bars nd red balls). Membrane-surface
HSPs (mHSP) are known as tumor antigens (r d). Intracellula HSPs can be kept bound to the
intracellular domains of the TMPs, such as epidermal growth factor receptor (EGFR) family members
on the cells and EVs. EVs are often taken up by recipient cells in a variety of ways such as endocytosis,
macropinocytosis, membrane fusion, and phagocytosis (right).
Meanwhile, ex-HSPs, including mHSP, HSP-rich exosomes, and oncosomes, play key roles
in intercellular communication in cancer, immunity, and various pathological conditions (Table 1).
HSPs are released from cells either by passive release, e.g., from damaged, stressed, or dead cells,
or active release, including secretion of HSP-containing exosomes. Free ex-HSPs have been also
called alarmin or chaperokine. Exosome HSPs were initially found in B cells, from which Hsp27,
Hsc70, Hsp70, and Hsp90 are released with exosomes upon heat shock stress [6]. Proteomics revealed
that oral cancer oncosomes re nriched in HSP90 mbers, HSP70 members, Hsc70, HSP105, and
chaperonin [1]. Notably, HSP90α is highly expressed in cancer cells and secreted to extracellular space
as free HSP90α [5] as well as cargo of oncosome [1]. Addition lly, HSP90β, TRAP1, and some members
of HSP70 are found in oncosomes [1]. However, the mechanism by which HSPs are incorporated
within the vesicles and their biological significance is still unknown. We here propose two models
of EV-HSPs: (i) intra-vesicular packaged HSPs and (ii) EV-membrane associated HSPs on the outer
surface of EVs (Figure 1).
Ex-HSP, EV-HSP, and mHSP can bind to cell surface receptors (i) stimulating intracellular signaling
pathways, (ii) taken up by endocytosis, or (iii) molecularly transferred to recipient cells (see Section 4).
Such recipient cells include various immune cells, cancer cells themselves, as well as potential cancer
stem cells [CSC, also known as cancer-initiating cells (CIC)], epithelial cells [7], cancer-associated
fibroblasts (CAFs), mesenchymal stem cells (MSC), tumor endothelial cells (TEC), and lymphatic
endothelial cells.
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Table 1. HSPs Found Extracellularly, in Exosomes and on Membranes.
Subfamily Name PrototypicalMembers Exosome HSP Free HSP Membrane HSP
HSP90
Hsp90α HSP90AA1
Hsp90β HSP90AB1
Gp96 Grp94/Hsp90B
TRAP1 Hsp75/Hsp90L
Cancer [1]
B cell [6]
3D Tumoroid [5]
HDF [9]
Tumor cells
APCs
Infected
erythrocyte
[10–12]
HSP70
HspA(1-12)
Hsp72
HspA1A/HspA1B
Hsc70, BiP HspA5
Hsp70B’ HspA6
See [2] in detail
Cancer [1,13]
B cell [6]
Mϕ [14],
Cancer [5,15]
Exercise [16]
Sarcopenia [17]
Cancer [18,19]
Small HSP
HspB(1–10)
Hsp27 HspB1
αB-crystallin HspB5
B cell [6], Sera,
body fluids [8]
Sera, body fluids
[8] ?
Large HSP Hsp105, Hsp110Grp170 Orp150 Cancer [1] ? ?
HSP40DnaJ
Tid1DnaJA3 [20]
ERdj4 DnaJB9
RME8 DnaJC13
? ? ?
HSP47 Colligin-2 RA-A47 ? RA sera [21] Chondrocyte [22]
Chaperonin TRiC
CCT
Hsp60, Hsp10
Cancer [1,23] DM [24] ?
Cell damages in pathological conditions induce expression and release of inducible types of HSPs, often found in
extracellular space as free forms, on the membrane surface, and in vesicles, although constitutively expressed types
of HSP is also found extracellularly. ?, unknown; RA, rheumatoid arthritis; DM, diabetes mellitus; HDF, human
dermal fibroblast; APC, antigen-presenting cell.
Small HSPs, including Hsp27 and αB-crystallin (αBC), have been detected in sera, cerebrospinal
fluids, and exosomes in various pathological conditions such as cancers, neurodegeneration, and
ischemia-reperfusion [8]. Extracellular small HSPs also play roles in cell–cell communication and
immunomodulation. Numerous studies have reported exosomal, free, and membrane-associated HSPs
(Table 1).
1.1. Roles of ex-HSP in Cancer Progression vs. the Host Immune System
A number of studies showed that tumor-derived exosomes promote cancer progression by
transferring oncogenic factors, including oncoproteins and oncogenic miRNA (oncomiR), to recipient cells
in the tumor microenvironment and in the pre-metastatic niche [25]. ex-HSP and EV-HSP play crucial
roles in cancer progression by binding to cell surface receptors such as CD91 [low-density lipoprotein
receptor-related protein (LRP1)/α2 macroglobulin receptor (A2MR)], promoting epithelial-mesenchymal
transition (EMT), migration, invasion, heterogeneity, metastasis, CSC-like properties, and drug resistance
in cancer cells and angiogenesis [26–32]. HSPs and oncoproteins within EVs could be a resistant-associated
secretory phenotype (RASP), co-transmissive to recipient cells and leading to cancer expansion and
malignant conversion of the tumor microenvironment (Figure 1). Several aspects and proof-of-concept
(POC) of RASP are summarized in Section 2.
Immune cells express receptors for HSPs, such as scavenger receptor expressed by
endothelial cells-1 (SREC-1), Toll-like receptors (TLRs), CD94 lectin-like natural killer receptor, and
CD91/LRP1/A2MR macroglobulin receptor, leading to endocytosis, antigen cross-presentation, T cell
cross-priming, and immune response. On the other hand, CD91 receptor is also expressed in cancer
cells and mediates ex-HSP90 signaling, which promotes cancer progression.
ex-HSP is also found on the membrane surface of cells and EVs. ER chaperones such as binding
immunoglobulin protein (BiP/HspA5) and Gp96/Grp94/Hsp90B1, known as tumor rejection antigen
(TRA), can translocate to the cytosol and eventually the surface of cells during ER stress induced
by drugs, UV irradiation, and microbial stimuli [33]. HSPs on the surface of cells and EVs can be
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recognized by CD91+ tumor cells, CD91+ fibroblasts, CD91+ SREC1+ TLR+ professional antigen
presentation cells (APCs), and CD94+ cytolytic immune cells. Therefore, ex-HSP, including mHSP, can
activate malignancy events in tumor cells and, in contrast, can trigger antigen cross-presentation and
cross-priming by APCs and stimulate the cytolytic immune cells such as natural killer (NK) cells and
CD8+ cytotoxic T lymphocytes (CTL) [34–37] (see Sections 3 and 4).
1.2. HSP90 and Co-Chaperones
HSP90 homologs are the major intracellular chaperones that ensure the correct folding and
function of proteins by interacting with various intracellular proteins [3,4,38,39]. HSP90 has been
implicated in promoting tumor growth and metastasis of breast cancer, leukemia, pancreatic cancer,
and ovarian cancer [40–42]. Four homologs of HSP90 are localized in different cellular compartments.
HSP90α, an inducible type of HSP, and HSP90β, a constitutively expressed type of HSP, are found in
the cytoplasm. Gp96/Grp94/Hsp90B1 is present in the endoplasmic reticulum (ER). Tumor necrosis
factor (TNF) receptor-associated protein 1 (TRAP1) exists in the mitochondria. TRAP1 is a homolog of
HSP90, although its molecular weight is 75 kD.
A number of studies have reported pathophysiological roles of HSP90 in various diseases, including
bacterial and viral infection [43–46], autoimmune diseases [47–51], cerebrovascular diseases [52–54],
and cancer. It is worth noting that the up-regulation of HSP90 in cancer is due to the fact that cancer
cells are constantly under stressful conditions such as acidosis, hypoxia, metabolic, and nutrient
deficiency [5,55,56]. High expression of HSP90 has been reported in various cancer types, including
lung cancer, breast cancer, colon cancer, and blood cancer, and correlates with poor prognosis [38,57].
Intracellular HSP90 (α, β) is often called “HSP90”. HSP90 is involved in the maturation and the
stabilization of a wide range of oncogenic client proteins crucial for oncogenesis and malignant
progression, such as signal transduction molecules Src and RAF1, cyclin-dependent kinase-4 (CDK4),
steroid hormone receptors, nitric-oxide synthase (NOS), Akt, PI3K, mutant p53 [58,59], ERBB2 (also
known as HER2) [60], and HIF-1α.
A recent study showed that HSP90 mediates MVB-to-plasma-membrane fusion [61]. This study
showed that HSP90 membrane-deforming ability promotes exosome release in vitro and in vivo. HSP90
possesses conserved amphipathic helix motifs that allow them to bind membranes and modulate their
physical properties. Membrane deformation only occurs when HSP90 dimer is in the open state and is
hindered by compounds that stabilize the closed conformation.
HSP90 has more than 10 cochaperones that cooperate with HSP90 for their clientele [39].
The stress-induced phosphoprotein 1 (Stip1) is also known as Hsp70-Hsp90 Organizing Protein
(HOP) co-chaperone, inhibiting the closed HSP90 dimer conformation. Lauwers et al. showed that
Stip1/HOP co-chaperone also promoted exosome release [61]. Cell division control 37 (CDC37) is
a kinome co-chaperone of HSP90, regulating the folding of most kinases in the cells. CDC37 plays
a crucial role as a co-chaperone of HSP90 in the stabilization of most kinases, including Src, RAF1,
and CDK4, and steroid hormone receptors [62–64]. Therefore, HSP90 and/or CDC37 are attractive
therapeutic targets against various cancers inasmuch as HSP90 and CDC37 are involved in the
functionalization of oncogenic proteins in many signaling pathways important for tumor progression,
survival, and resistance.
1.3. Inducibility of HSPs
According to their structural homologies, the HSP family members are classified into subfamilies
(Table 1). From another perspective, members of the HSP family are classified into two types:
an inducible type of HSPs and a constitutively expressed type of HSPs. The inducible HSPs are
expressed when cells are exposed to stress such as heat and hypoxia [4,65]. Nevertheless, a number of
studies have reported that both inducible and constitutive types of HSPs are often overexpressed in
malignant tumors and associated with the incidence as well as the progression of the disease and the
lymph node metastatic rate [56,66,67]. Consistently, inducible types of HSPs such as Hsp90α, Hsp72,
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Hsp70B’, and small HSPs are often found extracellularly and in EVs such as oncosomes, exosomes,
and ectosomes [1,18,68,69], while constitutive HSPs such as Hsp90β and Hsc70 have been found in
oncosomes [1] (Table 1).
Heat shock factor 1 (HSF1) is a canonical transcription factor that mediates cell stress and
induces the production of HSPs [3]. HSF1 often collaborates with hypoxia-inducible factor 1 (HIF-1),
mediating hypoxia stress response. HSP90 has more than 10 co-chaperones that define roles of the
HSP90/co-chaperone complex and their clientele spectrum. Cell division control 37 (CDC37) is a
kinome co-chaperone of HSP90, regulating the folding of most kinases in the cells. CDC37 induction is
reciprocally regulated by two SCAN-type transcription factors—myeloid zinc-finger 1 (MZF1) and
SCAN domain-containing protein 1 (SCAN-D1)—in prostate cancer [62,70].
Inducible types of HSP genes including HSP72, HSP70B’, and HSP27 are also induced by
intracellular matrix metalloproteinase-3 (MMP-3) and heterochromatin protein 1 (HP1), also known as
chromobox proteins (CBX) activate HSP genes [68].
Genetic amplification of HSP genes found in particular types of cancer can cause high expression
of HSPs [2], while genetic mutations in HSP genes have barely been found, suggesting epigenetic
involvement of HSPs in tumor mutation burdens (TMB).
1.4. Table of Contents
1. Introduction (Section 1)
2. RASP (Section 2)
3. Immunology of HSPs (Section 3)
4. Receptors for HSPs (Section 4)
5. Inducibility of HSPs and co-chaperone (Section 5)
6. HSPs as biomarkers detectable by liquid biopsies (Section 6)
7. HSP-targeted therapeutics (Section 7)
8. Conclusions (Section 8)
2. Resistance-Associated Secretory Phenotype (RASP)
2.1. HSP-Rich, Oncoprotein-Rich EVs
HSPs are often carried by EVs, e.g., exosomes, oncosomes, and microvesicles (MVs, also known
as ectosomes), as EV cargos and/or are associated on the surface of EVs [1,5] (Figure 1). EV-mediated
molecular transfer of oncoproteins such as mutant epidermal growth factor receptor (EGFR) and
amplified HSPs [2] can enhance carcinogenesis in surrounding recipient cells such as cancer cells
themselves, normal epithelial cells, fibroblasts, adipocytes, endothelial cells, macrophages, and other
immune cells [1,7,71]. As EV-free HSPs do, HSPs associated with the surface of EVs could activate
receptors such as CD91 and promote cancer cell EMT, migration, invasion, heterogeneity, angiogenesis,
metastasis, and drug resistance. Thus, EV-HSP and ex-HSP are major aspects of the RASP.
2.2. Ejection of Drugs and Antibodies with HSP-EVs
The RASP is also important in drug resistance inasmuch as cancer cells are able to eject molecularly
targeted drugs with EVs. Particularly, molecularly targeted anti-EGFR antibody drug Cetuximab is
able to bind to EGFR and inhibit EMT, a key step in cancer progression [7]; however, oral cancer cells
ejected Cetuximab with EGFR-containing EVs in response to administration of Cetuximab, indicating a
novel EV-mediated mechanism of drug resistance, a POC of RASP [72]. The antibody drugs can recruit
Fc receptor (FcR)-expressed immune cells, leading to phagocytosis by macrophages and/or cytolysis by
CTLs and by NK cells, although these anti-cancer immune cells can be released with EVs from cancer
cells. The EV-mediated ejection of drugs is a new manner of drug resistance in cancer cells as well as a
novel aspect of RASP.
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Anticancer drugs can cause the release of exosomes with HSPs, consistent with the concept of
RASP. As another POC, anticancer drugs caused the release of exosomes with HSPs from human
hepatocellular carcinoma cells, although the released HSP-exosomes elicited effective NK cell antitumor
responses in vitro [73], suggesting an immunostimulatory role of EV-HSP.
2.3. Release of Redundant Toxic Lipids
Lipid eﬄux is the other aspect of RASP. Redundant lipids are released from cells through the
release of lipid-layered EVs and lipid cholesterol eﬄux pump proteins. Such a pump overexpressed in
metastatic cancer cells was adenosine triphosphate (ATP)-binding cassette G1 (ABCG1) [74]. Targeted
silencing of ABCG1 resulted in the accumulation of EV lipid and triggered cell death in tumors,
suggesting that cancer cells can often release redundant toxic lipid, whereas loss of the ABCG1 pump
could trigger the accumulation of redundant, toxic lipids. Thus, the release of redundant, toxic EV
lipids can be the other aspect of RASP, whereas the accumulation of the redundant lipid could be toxic
to tumor cells, suggesting a conceptually and substantially novel therapeutic approach.
3. Immunomodulatory Roles of ex-HSP
Both the immunostimulatory and the immunosuppressive roles of ex-HSPs have been reported
(Table 2). The immunostimulatory ex-HSPs have been reported as HSP-peptide complex vaccines to
stimulate anti-tumor immunity. On the other hand, the immunosuppressive ex-HSP has been reported
as microbial HSP70/HSP60 inducing dendritic cell (DC) tolerance and stimulating immunosuppressive
cells such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) in tolerating
chronic inflammatory diseases such as rheumatoid arthritis (RA), type 1 diabetes, and atherosclerosis.
Table 2. Immunomodulatory Roles of Extracellular HSP as Vaccines.
Immunostimulatory HSP Immunotolerant HSP
Target diseases CancersInfectious diseases
Rheumatoid arthritis
Type 1 diabetes
Atherosclerosis
Multiple sclerosis
APC DCsMϕ Tolerogenic DCs
Immune cells Antigen-specific CD8+ CTLNK cells, NKT cells
MDSC
Treg
HSP antigens
Gp96 Grp94/TRA, BiP HspA5
HSP90, HSP70
Grp170 Orp150
Small HSPs
Microbial HSP70/HSP60
Effects
Antigen cross-presentation
T cell cross-priming
Tumor cytolysis
Immune tolerance
Anti-inflammatory
Immunosuppressive
MDSC, myeloid-derived suppressor cell; NK, natural killer; NKT, natural killer T; DC, dendritic cell; Mϕ, macrophage;
CTL, cytotoxic T lymphocyte.
3.1. Immunogenic Immunostimulatory Roles of ex-HSP
A number of studies reported antitumor immunostimulatory roles of HSP-peptides complex
vaccines. HSP-peptide complexes vaccination elicits anti-tumor immunity or other cells used as
the source of HSPs, suggesting that HSP-peptide complexes can be useful against cancers and
infectious diseases [75] (Table 3). From the aspect of the immune surveillance system, ex-HSPs released
from damaged cells as a danger signal and/or damage-associated molecular patterns (DAMP) can
stimulate professional APCs, followed by the release of cytokines and the expression of cell surface
molecules [76–78]. Moreover, ex-HSPs can promote the cross-presentation of HSP-bound peptide
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antigens to major histocompatibility complex (MHC) class I molecules in DCs, efficiently inducing
antigen-specific CTLs. The roles of HSPs stimulating both innate immunity and adaptive immunity may
be the molecular mechanism by which thermal stress bolsters the host immune system [79]. HSP peptide
complexes vaccination induces antigen cross-presentation by professional APCs such as DCs and
macrophages [80], thereby eliciting HSP-cross-primed antigen-specific CD8+ CTLs [34–37]. The HSP
peptides vaccines have been examined in cancer [81] and infectious diseases [82]. Immunogenicities of
Gp96 [83], Hsp90 [84], Hsp70 [80,85], and Grp170/Orp150 [86] have been examined.
Table 3. HSP-Based Immunotherapy Trials.
Concept, Material Disease Phase Note, Outcome
Autologous tumor-derived HSP
peptide complexes
(HSPPCs)
RCC
Melanoma III
Had clinical activities. In Phase III trials for
advanced melanoma and RCC patients, efficacy,
safety, and feasibility were demonstrated [34,87,88].
However, the limitations were apparent, and specific
alternatives have been developed.
CML, CRC
LymphomaPancreatic
cancer Gastric cancer
I/II
Autologous tumor-derived HSP
Gp96-peptide complexes
HSPPC-96
Vitespen®
Oncophage
RCC
Metastatic melanoma III
Feasible, devoid of significant toxicity, induced
clinical and tumor-specific T-cell responses in
vaccinated patients [89,90]. Promising in enhancing
survival of patients [91,92].
CRC, RCC
Glioblastoma
Lung cancer Melanoma
I/II Almost devoid of side effects aside from minorinjection-site reactions [93].
Preparation of
HSPPC-96
Pancreatic
adenocarcinoma I
No correlation between immune response and
prognosis. Feasible prep of HSPPC-96 [94].
HSPPC-96
+ GM-CSF + IFN-α Metastatic melanoma II
Gained tumor-specific T cell-mediated and NK
responses, but immune, clinical responses were not
gained compared with monotherapy [95].
Recombinant oncolytic
adenovirus overexpressing
HSP70 (H103)
Advanced solid tumors I
CR + partial response was 11.1% (3/27), and the
clinical benefit rate (CR + partial response + minor
response + stable disease) was 48.1%. CD4+ and
CD8+ T cells and NK cells were elevated [96].
Dendritic cells transfected with
HSP70 mRNA
(HSP70-DC)
HCV-related HCC I
Safe and feasible. Almost no adverse effects in grade
III/IV. CR without any recurrence (2), stable disease
(5), a progression of the disease (5). Infiltrating
CD8+T cells and granzyme B in tumors.
RCC, renal cell carcinoma; CML, chronic myelogenous leukemia; CRC, colorectal cancer; GM-CSF, granulocyte
macrophage colony-stimulating Factor; IFN, interferon; CR, complete response; HCV, hepatitis C virus; HCC,
hepatocellular carcinoma.
Cytotoxic immune cells including NK cells, CTL, and natural killer T (NKT) cells can recognize HSP
and HSP peptides expressed on the membrane surface of tumor cells and infected erythrocytes by the
receptor CD94, also known as killer cell lectin-like receptor D1 (KLRD1) [10,11], stimulating cytotoxicity
with induced release of granzyme B [10,97]. Anticancer drugs caused the release of exosomes with
HSPs from human hepatocellular carcinoma cells that elicited effective NK cell antitumor responses
in vitro, suggesting that exosome membrane surface HSP may stimulate NK cells [73].
In the 1990s–2000s, clinical trials of HSP-based vaccinations immunomodulation were carried
out, including autologous tumor-derived HSP peptide complexes (HSPPCs) [34,87,88], autologous
tumor-derived Gp96 peptide complexes (HSPPC-96, Vitespen®, Oncophage), and recombinant
oncolytic adenovirus overexpressing HSP70 (H103) [81] (Table 3). Intratumoral vaccination with a
recombinant oncolytic adenovirus overexpressing the HSP70 protein eradicated primary tumors as
well as inhibited the growth of established metastatic tumors in mice [81]. There were more than 150
medical centers worldwide in phase I/II/III clinical trials for many cancers. However, the limitations
were also apparent, and specific alternatives have been developed.
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DCs transfected with HSP70 mRNA (HSP70-DC) were tested in hepatitis C virus (HCV)-related
hepatocellular carcinoma (HCC) as a phase I dose-escalation clinical trial in 2015 [98]. No adverse
effects in grade III/IV were seen except one grade III liver abscess. Complete response (CR) without any
recurrence occurred in two patients, stable disease in five patients, and progression of disease in five
patients. Infiltration of CD8+ T cells and granzyme B in tumors was seen in immunohistochemistry.
ER chaperones such as binding BiP/HspA5 and Gp96/Grp94/TRA/Hsp90B1 play a multitude of
roles within the ER; however, many of these chaperones can translocate to the cytosol and subsequently
to the cell surface during ER stress [33]. On the cell surface or in the extracellular space, ER chaperones
can play immunostimulatory roles in cancer, appearing as DAMPs recognized by innate and adaptive
immune cells in the immune surveillance system in the host. Notably, BiP/HspA5 was found in
HNSCC cells-derived EVs, although it was decreased in the high metastatic EVs compared to the low
metastatic ones [1]. It was recently shown that phenotypically, distinct helper NK cells are required for
Gp96-mediated anti-tumor immunity [99].
3.2. Anti-Inflammatory, Immunotolerant Roles of ex-HSP
It has been shown that immunization with HSPs has protective effects in induced arthritis
models [100]. Immune reactivity to HSP has been found to result from inflammation in various
disease models and human chronic inflammatory conditions, such as RA, type 1 diabetes, multiple
sclerosis, and atherosclerosis [101]. Incubation with microbial HSP70 induced tolerogenic DCs and
promoted an immunosuppressive phenotype in MDSCs and monocytes [102]. It was shown that Tregs
(anti-inflammatory, immunosuppressive T cells) could recognize HSP70 self-antigens and enable Treg
selective targeting to inflamed tissues [103]. HSPs are therefore attractive candidates for therapeutics
in chronic inflammatory and autoimmune diseases, inducing long-lasting immune tolerance [77,104].
4. Receptors for ex-HSP and HSP Peptide Complex
Cell surface receptors known to be bound with ex-HSP90 are (i) CD91/LRP1/A2MR expressed on
tumor cells, immune cells, and EVs, (ii) toll-like receptors (TLRs), (iii) scavenger receptor expressed
by endothelial cells-1 (SREC-1), and (iv) CD94/KLRD1 expressed on killer cells. These receptors can
be involved in the activation of intracellular signaling pathways, endocytosis, and immune response.
The receptors expressed on the surface of EVs may hold ex-HSP90, as speculated in Figure 1.
4.1. CD91/LRP1/A2MR
CD91/LRP1/A2MR was shown to bind with HSP70, HSP90, and GP96 in macrophages [105]. Later
studies identified CD91 as a key receptor of ex-HSP90 in cancer cells and skin cells [106]. ex-HSP90 binds
to the subdomain II of CD91, and the intracellular NPVY motif (asparagine-proline-valine-tyrosine
motif) is essential for activation of Akt1/2 signaling [27]. CD91 is expressed in hypoxic stress, plays
a key role in endocytosis and transcytosis [107], and is thereby crucial in endocytosis of EVs and
ex-Hsp90 in a hypoxic microenvironment. It was recently re-demonstrated that the establishment
of tumor-associated immunity requires the interaction of HSPs with CD91 [108]. However, multiple
receptors for ex-HSPs have been reported (Table 4).
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Table 4. Receptors for ex-HSPs and HSP Peptide Complex.
Receptor Key events Expression Notes
CD91/LRP1/A2MR
Hypoxia response
EMT
Antitumor immunity
Cancer cell
APCDermal fibroblast
Exosome
1. Mediating ex-HSP-triggered endocytosis.
2. Mediating ex-HSP activation of MEK-ERK signaling and Akt signaling.
3. Hypoxia stimulates production of ex-HSP and ex-HSP/CD91 axis.
4. EMT can be stimulated by ex-HSP/CD91 axis.
5. Interaction of tumor-derived HSP with CD91 on APC is the
host-priming of T-cell antitumor activity.
TLR2
TLR3
TLR4
TLR9
Immune response
DAMP/PAMP signal
APC
Epithelial cell
1. Mediating ex-HSP DAMP signaling to stimulate innate immunity and
cytokine production.
2. CD14 and SREC-1 may be essential for the ex-HSP/TLR signaling.
SREC-1 Immune responseAntigen cross-priming APC
1. Crucial in APC-mediated immune response.
2. Essential for ex-HSP/TLR signaling.
3. Essential in HSP90-peptide complexes antigen uptake through
cross-priming of MHC class I molecules and entry into the class
II pathway.
CD94/KLRD1 Cytotoxicity targetingtumor and infected cells
NK cell
CD8+ CTL
NKT cell
1. CD94+ NK, NKT, and CTL can recognize Hsp70 and Hsp70 peptides on
cancer cells and infected RBC, stimulating cytotoxicity.
2. Evident ligands are (i) full-length HSP70, (ii) Hsp70 C-terminal domain,
(iii) a 14-mer peptide of Hsp70 N-terminus, TKDNNLLGRFELSG,
named TKD, (iv) membrane-surface HSP70 expressed on infected RBC,
(v) tumor-derived HSP-exosomes.
EMT, epithelial to mesenchymal transition; DAMP, damage-associated molecular patterns; PAMP, pathogen-associated molecular pattern; TLR, Toll-like receptor; KLRD1, killer cell
lectin-like receptor D1; SREC, scavenger receptor expressed by endothelial cells-1; MHC, major histocompatibility complex; RBC, red blood cells.
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4.2. Toll-Like Receptors (TLRs)
It was first shown that mitochondrial molecular chaperone Hsp60 was a putative endogenous
ligand of the TLR4 complex [109]. However, Hsp60 binding to macrophages occurred in the
absence of surface TLR4, although no cytokine response was induced by Hsp60 in TLR4-deficient
macrophages [105]. In addition, endogenous Hsp70 activated the Toll/IL-1 receptor signal pathway
similar to Hsp60 and pathogen-associated molecular patterns (PAMP) [110]. In this study, Hsp70
induced IL-12 and activated a promoter of endothelial cell-leukocyte adhesion molecule-1 (ELAM-1,
also known as E-selection or CD62E) in macrophages, while MyD88-deficient DCs did not respond
to HSP70 with proinflammatory cytokine production. In the same journal, it was also reported that
proinflammatory cytokine production induced by HSP70 was mediated by the MyD88/IRAK/NF-κB
signal transduction pathway, for which HSP70 could use TLR2 (for gram-positive bacteria) and TLR4
(for gram-negative bacteria) to transduce proinflammatory signal CD14-dependently [111]. These
studies indicated that (i) CD91/LRP1/A2MR can be a receptor of ex-HSPs and (ii) TLR2/4 can be
receptors of ex-HSPs as well. In the latter case, any pathogen such as lipopolysaccharide (LPS), any
other PAMP, or DAMP can be possibly contaminated within recombinant HSP fractions purified from
bacteria inasmuch as diminishing contamination of pathogens may be difficult methodologically and
technically. It has also been suggested that HSPs augment the ability of associated innate ligands
such as LPS to stimulate cytokine production and DCs maturation [112]. Nevertheless, co-factors,
co-receptors, co-stimulatory factors, or adaptor proteins might be of interest on the cell surface.
ex-HSPs/mHSPs on the surface of EVs can be recognized by receptors expressed on recipient cells,
although multiple pathways have been suggested (Figure 2).
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4.3. SREC-1
Scavenger receptors (SRs) are cell surface receptors for degenerated lipoproteins involving
cholesterol and lipoprotein metabolism. SRs were first found in macrophages, whose SRs were used for
internalization of denatured lipoproteins into cells. Interestingly, HSP70.PC vaccine activation of T cells
required both TLR signaling and SREC-1 [113,114]. HSP70 peptide complex isolated from tumor-DC
fusions (HSP70.PC-F) induced potent antitumor immunity. In this study, HSP70.PC-F-induced
antitumor immunity depended on intact TLR signaling in immunized animals, while Tlr2/Tlr4-silenced
mice did not respond to the HSP70 vaccine. Notably, TLR-dependent tumor cell-killing was inhibited
by SREC-1 knockdown in DCs, suggesting a crucial role of SREC-1 in HSP70-mediated tumor
immunity [113,115].
SREC-1 also plays a significant role in HSP90-mediated antigen cross-presentation [116]. HSP90-
ovalbumin (OVA) peptide complexes bound to SREC-1 expressed on APCs. SREC-1 mediated
internalization of HSP90-OVA polypeptide complexes via a Cdc42-regulated dynamin-independent
endocytic pathway from early endosomes to recycling endosomes. It was shown that SREC-1 plays a
primary role in HSP90-peptide complexes’ antigen uptake via cross-priming of MHC class I molecules
as well as entry into the class II pathway [117].
In spite of ex-HSP, SREC-1 modulates the function of TLRs with essential roles in innate
immunity. It has been shown that SREC-1 promoted dsRNA-dependent activation of TLR3 in
monocytes [118]. SREC-1 also involved TLR4 entry into lipid microdomains and triggered the
release of inflammatory cytokine in macrophages [119]. It was also shown that SREC-1 promoted
dsRNA/CpG DNA-mediated TLR3/TLR9 activation followed by activation of NF-κB, interferon
regulatory factor 3 (IRF3), and mitogen-activated protein kinase (MAPK) pathways, which trans-activate
cytokine genes [120]. Additional SRs can bind with ex-HSP70, including lectin-like oxidized LDL
receptor-1 (LOX-1), a member of both the c-type lectin receptor family and the SR family, as well as
FEEL-1/CLEVER-1/STABILIN-1, containing multiple epidermal growth factor (EGF)-like repeats [121].
4.4. CD94, Killer Cell Receptor
CD94, also known as killer cell lectin-like receptor D1 (KLRD1), is a C-type lectin expressed
on the surface of NK cells, CTL, and natural killer T (NKT) cells [10]. The CD94+ killer cells can
recognize HSP70 and HSP70 peptides on the membrane surface of cancer cells and Plasmodium
falciparum-infected erythrocytes [11], stimulating cytotoxicity with the induced release of granzyme
B [10,97]. For activation of CD94+ killer cells, evident HSP-ligands are full-length ex-HSP70 [10],
Hsp70 C-terminal domain, TKD (a 14-mer peptide derived from the N-terminal sequence of Hsp70
TKDNNLLGRFELSG, aa 450–463) [11,97,122,123], mHSP70 expressed on infected red blood cells [11],
and tumor-derived HSP-exosomes [73]. IL-15/TKD treatment increased the proportion of CD94+
CD3+CD56+ NKT cells [122].
5. Inducible Mechanisms for HSPs
Heat shock factor 1 (HSF1) is a canonical transcription factor that mediates cell stress and induces
the production of HSPs, although several additional transcription factors recently identified can be
involved in cancer progression and resistance [3]. For expression of HSP genes and other target
genes, HSF1 trimers bind to the heat shock elements (HSE) often located in promoter regions of
these genes. It has been shown that PI3K-PKCδ signal mediates the activation of HSF1 and HIF-1,
which co-trans-activate HSP genes [124], whose promoter regions are often enriched in the HSE and
the hypoxia-responsive elements (HRE). Many types of HSP are induced upon hypoxia, including
HSP70 [125], Orp150/Grp170 [126], Hsp27 [127], and HSP90 [9,128], along with the induction of
vascular endothelial growth factor (VEGF) [129] and heme oxygenase-1 (HO-1) [130].
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The hypoxic environment in tumors is essential for the production of ex-HSP. Tumor hypoxia is a
distinguishing feature of solid tumors resulting from the inadequate oxygen delivery of the abnormal
blood vessels supplying the tumor that cannot meet the demands of the rapidly proliferating cancer
cells [131–133]. For example, molecular targeting of C-X-C motif chemokine receptor 4 (CXCR4) on
vascular endothelial cells induced tumor angiogenic inhibition triggered necrosis (TAITN) in oral
cancer, although HIF-1α was induced in the hypoxic and the necrotic tumor tissue [134]. Intratumoral
hypoxic stress induces HIF-1 that trans-activates a number of target genes, including HSP90AA1
gene encoding HSP90α [5,9,135], ATP-binding cassette (ABC) transporter genes such as ABCG1 and
ABCG2 [74], MMP genes, and connective tissue growth factor (CTGF)/CCN2 gene [136,137].
Secreted ex-HSP90α and ex-HSP90βwere found in the conditioned media of breast cancer cell
lines, in which HIF-1α is constitutively active [26]. In breast cancer MDA-MB-231 cells, the secreted
ex-HSP90 increased cancer cell survival in a hostile hypoxic environment via CD91-mediated activation
of Akt, a kinase mediating cell survival. The three-dimensional (3D) tumor organoid (tumoroid) culture
system enabled reproduction of intratumor hypoxia with CSC properties from which ex-HSP90 was
abundantly released, although not from two-dimensional (2D)-cultured normoxic cells [5,138].
HIF-1 signaling stimulates the migration of human dermal fibroblast (HDF) by inducing the
HSP90α secretion into the extracellular environment [9,139]. The secreted ex-HSP90α, in turn, promotes
the hypoxia cell motility signaling. Interestingly, recombinant HSP90α treatment greatly doubled the
hypoxia effect on HDFs. On the other hand, antibody blockade of ex-HSP90α completely abrogates
the hypoxia–HIF-1 pathway-stimulated HDF migration [106,140]. Transforming growth factor-alpha
(TGFα), a member of the EGF ligand family, also stimulates the secretion of HSP90α [106]. CD91/LRP1
has been identified as a key receptor of ex-HSP90 [106]. It is thought that EV-HSP90 could also bind to
and stimulate LRP1 on the surface of recipient cells (Figure 2). Therefore, tumor hypoxia induces LRP1
and HSP90 expression and LRP1-HSP90 interaction on the surfaces of cells, and EVs could promote
tumor growth.
HSP90 co-works with more than 10 types of co-chaperones [63]. Cell division control 37 (CDC37)
is a kinome co-chaperone of HSP90 [62,70]. Notably, two SREZBP-CTfin51-AW1-Number 18 cDNA
(SCAN)-type transcription factors—myeloid zinc-finger 1 (MZF1) and SCAN domain-containing
protein 1 (SCAN-D1)—were shown to reciprocally regulate cell division control 37 (CDC37); the
former activates and the later represses the CDC37 gene [62,70]. These transcription factors regulate
genes encoding molecular chaperones and co-chaperones and are thus crucial in cancer progression
and resistance.
Recent studies have discovered that intracellular matrix metalloproteinase-3 (MMP-3) and
heterochromatin protein 1 (HP1), also known as chromobox proteins (CBX), activate HSP72, HSP70B’,
and HSP27 [68].
6. HSPs as Biomarkers Detectable by Liquid Biopsies
HSPs are often released from tissues into body fluids upon cellular/tissue stress, damage, cell death,
hypoxia in cancer progression, and other various pathological conditions, known as alarmins, DAMP or
chaperokines (Figure 3). These released HSPs are cell-free proteins, protein complex, ribonucleoprotein
(RNP) complex [2], membrane-associated HSPs, vesicle surface-associated HSPs, or cargos packaged
in EVs such as exosomes and oncosomes [141].
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6.1. Serum HSP Biomarkers
Hsp70 is often found on the plasma membrane of malignant tumors and released into the blood
circulation with exosomes. It was suggested that an mHSP70 phenotype correlates with tumor
aggressiveness, whereas such mHsp70s are targeted by cytolytic immune cells such as NK cells. It was
indeed shown that squamous cell non-small-cell lung cancer (NSCLC) and adeno NSCLC patients
harbored significantly higher levels of serum Hsp70 than healthy controls [15]. Serum Hsp70 levels
were significantly correlated with the gross tumor volume in both types of NSCLC. This study also
indicated that NK cells can be more active in squamous cell carcinoma (SCC) than adenocarcinoma,
suggesting different levels of NK immunity. Even in pet dogs, serum Hsp70 levels were demonstrated
as a potential diagnostic biomarker for spontaneous round cell tumors [142]. Free HSPs and exosome
HSPs can be attractive biomarkers for diagnosis and prognosis in cancer, including HNSCC [1] and
prostate cancer [5] as well. EVs secreted by high-metastatic HNSCC cells contained high amounts of
TRAP1, Hsp90β, Hsp90α, Hsp105/HspH1, and Hsp72 compared to low-metastatic HNSCC cells [1].
Indeed, patients harboring TRAP1-high or HSP90β-high tumors are correlated with poor prognosis
compared to low-expression patients’ groups. In HNSCC patient cases, high expression of TRAP1 and
Hsp105 was found over the stages (I to IV), while HSP90α/β-high expression cases were increased in
later stages (stages II to IV) compared to stage I cases [1]. Besides, ex-HSP90αwas abundantly secreted
by enlarged 3D hypoxic tumoroids formed with castration-resistant prostate cancer (CRPC) cell line
PC-3, although not by smaller tumoroids nor by 2D-cultured cells [5]. In this model, ex-HSP90α was
abundantly released, while EV-HSP90αwas barely detected.
Besides, serum Hsp70 has been shown to be increased after exercise and acute terms through
induction by IFN-γ and elevated body temperature, i.e., thermal stress [16]. For example, after ironman
triathlon races, Hsp70 was released into the blood circulation as a function of exercise duration,
indicating that Hsp70 is released into circulation upon tissue damages, while anti-inflammatory
cytokines were induced, and pro-inflammatory cytokine response was minimal [143]. Recent studies
indicated that systemic ex-Hsp72 in plasma is associated with a potential diagnostic or predictive
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biomarker of sarcopenia [17]. Consistently, it has been shown that sarcopenia is associated with
increased systemic inflammation in older adults.
Extracellular small HSPs have been demonstrated to be involved in various pathological conditions.
The most frequently studied member of a small HSP family is Hsp27/HspB1, which is overexpressed
in various cancers and is associated with tumor metastasis, progression, and a poor prognosis.
Elevated serum levels of HSP27 have been detected in patients with breast [144], ovarian [145], and
colon cancer [146], hepatocellular carcinoma [147], gastric adenocarcinoma [148], as well as chronic
pancreatitis [149], diabetic neuropathy [150], and insulin resistance [151]. In addition, serum HSP27 has
been detected in patients with atherosclerosis [152,153], acute coronary syndrome, and reperfusion after
ischemic clamping during heart bypass surgery [154]. HSP27 has also been found in the cerebrospinal
fluid during spinal cord and brain ischemia [155].
6.2. Serum Antibodies against HSP (60, 70, and 90)
Besides, HSPs belong to TAAs overexpressed in various human cancers. Elevated HSP can
stimulate the immune system to produce anti-HSP autoantibodies (AAbs). AAbs against HSPs have
been identified in the circulation of various cancer patients [156]. Because of their specificity and
stability in the sera, AAbs against HSPs can be also attractive biomarkers for the development of less
invasive serological tests for the diagnosis and the prognosis of cancer.
6.3. Cancer Liquid Biopsies and HSPs
Tissue biopsies are commonly used for diagnostic, prognostic, and treatment purposes, despite
a lot of limitations such as its invasive nature, failure to reflect the tumor heterogeneity, and the
discomfort suffered by the patient. Liquid biopsies are considered as a non-invasive alternative to tissue
biopsies and can provide advanced diagnostic information from a small amount of body fluid such as
blood. Notably, liquid biopsy has attracted attention as an important technique for early detection and
diagnosis of cancer and various pathological conditions [157] by using blood [158,159], saliva [160–162],
urine [163–165], stool [166,167], semen, sweat, tear, nasal mucus, breast milk, cerebrospinal fluid,
amniotic fluid, and malignant ascites [168–171] (Figure 3).
Liquid biopsy can derive genetic, epigenetic, and proteomic information of multiple cancers at
one time, estimate the cellular and the molecular characteristics of cancer-associated cells, and monitor
the response to different anticancer therapies [172]. Blood analytes are composed of circulating cell-free
DNA (cfDNA), including mutant DNA and methyl DNA, circulating cell-free RNA (cfRNA) including
mRNA and circulating cell-free microRNA (cfmiRNA), cell-free proteins, circulating tumor DNA
(ctDNA), EVs such as exosomes, circulating tumor cells (CTCs), tumor-educated blood platelets (TEPs),
and metabolites [172–177]. Liquid biopsies of CTCs, circulating cell-free materials, and EVs are useful
for early detection of cancer and prognostic assessment of cancer progression dynamics [157,178].
Thus, ex-HSP and exosome-HSPs in body fluids may be useful for theranostics of cancers in
combination with other biomarkers detectable by liquid biopsies.
7. HSP-Targeted Therapies
Targeting HSPs at protein and mRNA levels has been tried inasmuch as HSPs are anti-apoptotic
resistant chaperones in tumor cells, although extracellular and vesicular HSPs are under investigations.
In this section, we review HSP-targeted inhibitors, HSP mRNA-targeted therapeutics, clinical trials,
and potential nano-vesicles delivering drugs.
7.1. Clinical Trials of HSP90 Inhibitors
The first discovered HSP90 inhibitor was geldanamycin (GA), belonging to the benzoquinone
ansamycin antibiotics [179]. GA was found to arrest the tumor proliferation by inhibiting the Src tyrosine
kinase activity, although it was unable to directly inhibit the activity of purified Src kinase [180,181].
Further studies revealed that the anti-proliferative effect of GA resulted from its binding to the ATP
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binding pocket of HSP90. Consequently, GA inhibited the binding of the client proteins to HSP90 and
led to the proteasomal degradation of these proteins. These results proved that the efficacy of HSP90
inhibitors is closely related to their binding ability with HSP90.
In order to reduce the hepatotoxicity and increase water solubility, the structure of GA was modified
to generate 17-allylamino-17-demethoxygeldanamycin (17-AAG), also known as tanespomycin.
The 17-AAG was the first HSP90 inhibitor used in human clinical trials [182] (Table 5). Although
the 17-AAG is still insoluble in water, a considerable effect was observed in clinical phase I trials.
In addition, the phase II trials were performed on patients with metastatic breast cancer and melanoma,
and side effects such as tiredness, nausea, diarrhea, and liver damage were reported, by which the use
of 17-AAG was stopped [183].
Table 5. HSP-Based Trials.
Concept Disease Phase Note, Outcome
HSP90 inhibitor
17-AAG
Metastatic breast cancer
Melanoma I/II
Side effects occurred such as tiredness, nausea, diarrhea, and
liver damage. HSP70 was induced in PBMC [184,185].
HSP90 inhibitor Ganetespib® NSCLC III Not positive in unselected NSCLC. Therefore, drug
development was halted. More promising in ALK-rearranged
NSCLC patients.HSP90 inhibitor Retaspimycin
® NSCLC III
HSP90 inhibitor AUY922
NSCLC III
Stage IV NSCLC II Active particularly among patients with ALK rearrangementsand EGFR mutations [186].
HSP90 inhibitor AUY922
+ Erlotinib
EGFR-mutant lung
cancer I/II
Evaluated in acquired resistance to EGFR-TKI. Partial
responses, but the duration of treatment was limited by
toxicities, especially night blindness. Did not meet its primary
endpoint [187].
HSP90 inhibitors CRPC I/II Negligible anticancer activity and dose-limiting toxicityprofiles [188].
Oral HSP90 inhibitor
PF-04929113 (SNX5422)
Recurrent, refractory
hematologic
malignancies
I
Alternate-day oral dosing at 74 mg/m (2) for 21/28 days was
tolerated with reversible toxicity. Myeloma and lymphoma
patients were responsive [189].
Oral HSP inhibitor Debio0932 NSCLCBreast cancer I Has limited clinical activity with manageable toxicity [190].
HSP27-targeted antisense
oligonucleotide
OGX-427 Apatorsen®
Squamous NSCLC I Tested, as overexpression of Hsp27 in squamous NSCLC is amechanism of chemoresistance.
Metastatic
non-squamous
NSCLC
II
A combination of carboplatin and pemetrexed was evaluated.
Well tolerated but did not improve outcomes in the first-line
setting [191].
Advanced bladder
cancer II A combination of cisplatin and apatorsen was tested.
CRPC II/III Has shown good biological activity [188].
HSP70 inhibitor
15-deoxyspergualin Metastatic breast cancer II Neuromuscular side effects with no benefit for disease.
Anti-HSP70 antibody
recognizing TKD NSCLC I/II
Safe in phase I. Evaluated in combination with radio-,
chemotherapy.
17-AAG, 17-allylamino-17-demethoxygeldanamycin; PBMC, peripheral blood mononuclear cells; NSCLC,
non-small-cell lung cancer; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; CRPC,
castration-resistant prostate cancer.
Several HSP90 inhibitors, including Ganetespib, AUY922, and Retaspimycin, were tested in phase
III clinical trials in non-small cell lung cancer (NSCLC), although none were positive in unselected
NSCLC [192]. Therefore, drug development was halted. However, results were more promising
in anaplastic lymphoma kinase (ALK)-rearranged NSCLC patients. Overexpression of Hsp27 in
squamous NSCLC is a mechanism of chemoresistance. Therefore, Hsp27 inhibitor Apatorsen was
tested in squamous NSCLC.
A number of HSP90 inhibitors inhibit ATP hydrolyzing activity by binding to the ATP-binding site
of HSP90 and suppress its chaperone function required for client proteins conformation changes. Such
an effect of HSP90 inhibitors decreases the binding affinity of the client proteins to the HSP90, resulting
in their dissociation from HSP90. The client proteins become structurally unstable, ubiquitinated, and
degrade by the proteasome. The reduction of client oncoproteins prevents the growth of cancer cells.
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The most surprising finding with HSP90 inhibitors is their higher affinity and selectivity towards the
tumor cells and not to the normal cells [193].
To overcome this drawback, combining the HSP90 inhibitors with other drugs [194,195] and/or
radiation [196,197] has been investigated, although these are still under investigation. Most recently,
an HSP90 inhibitor XL888 in combination with a v-Raf murine sarcoma viral oncogene homolog B1
(BRAF) inhibitor Vemurafenib had clinical activity in patients with advanced BRAF-V600-mutant
melanoma with a tolerable side-effect profile [198], while it was indicated that HSP90 inhibitors warrant
further evaluation in combination with current standard-of-care (SOC) BRAF plus MEK inhibitors in
BRAF-V600-mutant melanoma (Table 5).
Kang et al synthesized and biologically evaluated a novel 18F-labeled 5-resorcinolic triazolone
derivative (1, [18F] PTP-Ganetespib) based on Ganetespib, a most promising candidate among several
HSP90 inhibitors under clinical trials, which entered “phase III” clinical trials for cancer therapy [199].
[18F] PTP-Ganetespib was highly taken up in breast cancer cells, including triple-negative breast cancer
(TNBC) MDA-MB-231 and Her2-negative MCF-7 cells. [18F] PTP-Ganetespib was retained longer in
the tumor than other organs, shown in biodistribution and microPET imaging studies.
7.2. Potential Limitations of HSP90 Inhibitors
ATP-independent activities of HSP90—although most HSP90 inhibitors target the ATP binding
site, chaperokine activities of ex-HSP90 and EV-HSP90 are not dependent on the ATP hydrolyzing
activity. EV-HSP90 incorporated within the EVs could be propagated in the tumor microenvironment
and in body fluids and is not easily targeted by the small molecule chemical inhibitors. EV-mediated
RASP could promote the release of HSP90 inhibitors with EVs.
The physiological necessity of HSP90 and target cell selectivity—HSP90 is required for homeostasis
of normal, non-cancerous cells. Without a cancer cell-targeted drug delivery system (DDS), HSP90
inhibitors could be harmful and toxic to normal cells, leading to unfavorable side effects (potential
usefulness of nano-vesicles such as DDS is mentioned below.) Notably, HSP90β is a housekeeping
protein whose activities are essential in all cells. Besides, HSP90α is an inducible protein essential for
physiological stress response in normal cells.
HSP90/HSF1 feedback system—HSP90 binds to and keeps the inactivated status of HSF1,
whereas HSP90 inhibitors trigger the release of HSF1 from the HSP90/HSF1 complex and the
subsequent trans-activation of HSP genes, e.g., a compensatory increase in HSP70 expression
and other numerous genes, which induce a stress response and resistance of cancer cells. HSF1
is a stress-responsive transcription factor and has been reported as a multi-faceted modulator of
tumorigenesis [66,200–204]. In response to heat shock stress [68,202,205,206], intracellular accumulation
of misfolded proteins [3,207–212], or tumor-promoting signaling such as phosphatidylinositol 3-kinases
(PI3K)-Akt-mTOR signaling [200,213], HSF1 is activated and translocated into the nucleus, where
it binds to HSP genes promoters and fosters their transcription. HSF1 transcriptional activity can
be regulated through feedback inhibition by HSP90 [38,214–216]. Therefore, HSP90 inhibitors could
trigger the release of HSF1 from the HSP90/HSF1 complex and de-repress HSF1, which is then able to
trans-activate a number of HSP genes and oncogenes [214,215]. Importantly, these stress-responsive
genes and the up-regulation of oncogenes enable tumor cells to respond to a variety of stresses and
allow them to thrive in unfavorable growth conditions. Thus, the HSP90/HSF1 feedback system could
counteract the cell-killing (cytotoxic) effect of HSP90 inhibitors.
7.3. HSP70 Inhibitors
The human HSP70 family contains several highly homologous members composed of N-terminal
nucleotide-binding domain (NBD) containing ATPase activity, substrate-binding domain (SBD),
and C-terminal EEVD domain binding to co-chaperone DnaJ/HSP40, nucleotide exchange factors
(NEF), and B-cell lymphoma 2 (BCL2)–associated anthanogene 3 (Bag3) [2]. Inhibitors binding
each domain have been developed and tested. The HSP70 SBD is targeted by ADD70 polypeptide,
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2-phenylethynesulfonamide (PES/Pifithrin µ), PES-CI, and A8 peptide. The HSP70 NBD is targeted
by a number of inhibitors, including VER155008, MKT-077, and YK5. The HSP70 EEVD domain is
targeted by YM-1, Myricetin, MAL3-101, and 15-deoxyspergualin [217,218]. The 15-deoxyspergualin
was tested in a phase II clinical trial in metastatic breast cancer, although neuromuscular side effects
with no benefit for the disease were reported [219]. See our recent review of the HSP70 family and
inhibitors for more information [2].
7.4. Anti-mHSP70 Antibody
Antibody based-therapy had been considered the best strategy for targeting HSP70, although
it was hindered by the lack of specificity to tumor markers [220]. However, Stangl et al.
developed a monoclonal antibody mHsp70.1 specifically recognizing the extracellular 14-mer motif
TKDNNLLGRFELSG (TKD) of membrane-bound HSP70 (mHSP70). It is worth noting that the
membrane form of Hsp70 is frequently expressed in tumors but not on normal cells [221]. The safety
of CmHsp70.1 has been proven, and it passed the phase I clinical trial and the phase II clinical trial for
NSCLC in combination with radiochemotherapy in 2005 [222].
7.5. HSF1 Inhibitors
The bioflavonoid quercetin was the first approach to inhibit transcriptional factor HSF1, thereby
inhibiting the HSP70 induction at the mRNA levels [223]. Subsequently, more potent compounds
inhibiting HSF1 are a benzylidene lactam compound, KNK437 [224], and a triazole nucleoside
analog [225]. However, targeting HSF1 blocks the transcription of all stress-inducible HSPs and other
transcriptionally targeted genes, thus disturbing the housekeeping functions of these proteins in
normal cells and various pathophysiological conditions [226].
7.6. HSP40 Inhibitors
HSP40 is a co-chaperone of HSP70, stimulating HSP70 ATPase activity and thereby compromising
HSP70 functions. A series of phenoxy-N-arylacetamides was identified to directly bind to bacterial
Hsp40/DnaJ and disrupted Hsp70/Hsp40-mediated luciferase refolding by binding to DnaJ [227].
Chalcone C86 was recently identified to interact with Hsp40, thereby destabilizing androgen
receptor variants-mediated transcriptional activities in CRPC [228].
7.7. HSP110 Inhibitor
HSP110, an HSP70 nucleotide-exchange factor, is necessary for cancer cell survival. A mutant of
HSP110 (HSP110DeltaE9) not only diminished HSP70 chaperone activity but also sensitized cancer
cells to anticancer drugs both in vitro and in vivo [229].
7.8. HSP27 Inhibitors
HSP27/HspB1 is a potent cytoprotective chaperone, and it is overexpressed in many cancer types;
thus, it is an attractive target in cancer therapy. However, HSP27-directed therapy is difficult, as HSP27
is an ATP-independent chaperone, unlike other HSPs [230]. There are three approaches that have been
reported for HSP27 inhibition: (i) by small molecules inhibitors that directly bind to HSP27 and inhibit
its downstream pathways. These compounds include RP101 (Brivudine) [231] and Zerumbone [232].
Zerumbone was directly inserted between the disulfide bonds in the HSP27 dimer and modified normal
HSP27 dimerization; (ii) using peptide aptamers, which specifically bind to HSP27 and disturb the
dimerization and the oligomerization of the chaperone [233]; (iii) OGX-427 antisense oligonucleotides
that target HSP27 mRNA [234]. It is worth noting that both small molecule inhibitors of HSP27 and
peptide aptamers are used to enhance chemotherapy efficacy of anti-cancer drugs, as they are not
effective on their own. On the other hand, OGX-427 is the only HSP27 inhibitor that successfully
passed through phase I clinical trials and is currently being tested in phase II/III [188,235].
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7.9. HSP mRNA-Targeted Therapy
The above-mentioned OGX-427 is most promising as HSP27 mRNA-targeted therapy. Besides,
HSP70 siRNA was used for “blocking heat shock response” in MnO2/Cu2-xS-based multimode imaging
diagnostic and advanced single-laser irradiated photothermal/photodynamic therapy [236]. In this
study, Cao et al. used MnO2 to relieve tumor hypoxia inasmuch as MnO2 was reduced to Mn2+ ion
and triggered the decomposition of H2O2 into O2 in the tumor acidic microenvironment.
HSP90-rich EVs are released by metastatic cancer cells, whereas small interfering RNA (siRNA)
double-targeting HSP90α and HSP90β mRNAs efficiently decrease cancer cell viability, indicating
a novel concept of HSP90 mRNA-targeted oligonucleotide therapeutics [1]. Most HSP90 inhibitors
target ATP-binding pockets, although the ATP-dependent activity of HSP90 in cells and extracellular
space has been assumed.
7.10. Nano-Vesicles as Potential DDS
Nanovesicles such as exosomes and liposomes were recently examined as DDS delivering drugs.
Nanovesicles delivering HSP90 inhibitors or HSP mRNA-targeted RNAi may be effective in killing
cancer cells or inhibiting tumor heat shock responses. Specific vesicle-surface molecules, e.g., cancer-cell
targeting ligands, “do not eat me” signals, and masking “eat me” signals, may be required for selective
targeting on cancer cells and avoid phagocytosis by macrophages.
Nevertheless, the tumor microenvironment can be also targeted, e.g., CXCR4+ TEC was targeted
by AMD3100 to induce tumor angiogenic inhibition triggered necrosis (TAITN) [134]. Therefore, HSP
in TEC, CAF, tumor-associated macrophages (TAM), and immunosuppressive cells could be targeted
in the future.
8. Conclusions
Extracellular HSPs including HSP90 (α, β, Gp96, Trap1), HSP70, and large and small HSPs have
been found in exosomes, oncosomes, membrane surfaces, as well as free HSP in cancer and various
pathological conditions, also known as alarmins. Oncosomes released by tumor cells are a major aspect
of RASP by which immune evasion can be established. Releases of ex-HSP and HSP-rich oncosomes are
essential in RASP, promoting cancer progression and resistance against host immunity and therapeutic
stress. RASP of tumor cells can eject anticancer drugs. Cytotoxic lipids can be also released from
tumor cells as RASP. ex-HSP and mHSP play immunogenic roles recognized by APCs, leading to T
cell cross-priming, as well as by CD94+ NK cells, leading to tumor cytolysis, whereas ex-HSP/CD91
signaling in cancer cells promotes cancer progression. HSP genes are canonically activated by HSF1
and hypoxia signaling mediated by HIF-1, while matrix metalloproteinase (MMP)-3 and HP1 are novel
positive regulators for inducible types of HSPs. HSPs in body fluids are potential biomarkers analytical
by liquid biopsies in cancers and tissue-damaged diseases. Some HSP-based vaccines, inhibitors, and
RNAi therapeutics are promising in cancer therapy.
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Abbreviations
17-AAG 17-allylamino-17-demethoxygeldanamycin
A2MR Alpha 2 macroglobulin receptor
AAb Autoantibody
ABC ATP-binding cassette
APC Antigen-presenting cell
BiP Binding immunoglobulin protein
CAF Cancer-associated fibroblast
CBX Chromobox protein
CDC37 Cell division control 37
CDK Cyclin-dependent kinase
CIC Cancer-initiating cell
CML Chronic myelogenous leukemia
CR Complete response
CRC Colorectal cancer
CRPC Castration-resistant prostate cancer
CSC Cancer stem cell
CTC Circulating tumor cell
ctDNA Circulating tumor DNA
CTGF Connective tissue growth factor
CTL Cytotoxic T-lymphocyte
CXC Cysteine-X-cysteine motif
DAMP Damage-associated molecular pattern, danger-associated molecular pattern
DM Diabetes mellitus
EGFR Epidermal growth factor receptor
EMT Epithelial to mesenchymal transition
EV Extracellular vesicle
EV-Hsp Extracellular vesicle-associated heat shock protein
ex-Hsp Extracellular HSP
FcR Fragment-crystallizable receptor
GP96 Glycoprotein 96
GRP Glucose-regulated protein
HIF Hypoxia-inducible factor
HP1 Heterochromatin protein 1
HSF Heat shock factor
HSP Heat shock protein
ILV Intra-luminal vesicle
IRAK IL-1 receptor-associated kinase
LPS Lipopolysaccharide
LRP1 Low-density lipoprotein receptor-related protein 1
MDSC Myeloid-derived suppressor cells
MHC Major histocompatibility complex
MMP Matrix metalloproteinase
MSC Mesenchymal stem cell
mTOR Mammalian target of rapamycin
MV Microvesicle
MVB Multi-vesicular body
Myd88 Myeloid differentiation 88
MZF1 Myeloid zinc finger 1
NK Natural killer
NSCLC Non-small-cell lung cancer
OncomiR Oncogenic microRNA
ORP150 Oxygen-regulated protein 150
OSCC Oral squamous cell carcinoma
PAMP Pathogen-associated molecular pattern
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PD-1 Programmed cell death-1
PD-L1 Programmed cell death-ligand 1
PI3K Phosphatidylinositol 3-kinases
POC Proof of concept
RA Rheumatoid arthritis
RASP Resistance-associated secretory phenotype
RCC Renal cell carcinoma
SCAN SREZBP-CTfin51-AW1-Number 18 cDNA
SCC Squamous cell carcinoma
SR Scavenger receptor
SREC Scavenger receptor expressed by endothelial cells-1
TAA Tumor-associated antigen
TAITN Tumor angiogenic inhibition triggered necrosis
TLR Toll-like receptor
TRAP-1 TNF receptor-associated protein-1
Treg Regulatory T cells
Tumoroid Tumor organoid
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